You are in:Home/Publications/Addition of Sofosbuvir to the Standard Pegylated Interferon-Ribavirin Therapy in Treatment-naive &-experienced Patients with Chronic Hepatitis C Infection

Dr. Hany Ragheb Abdelbaky Ahmed Elkholy :: Publications:

Title:
Addition of Sofosbuvir to the Standard Pegylated Interferon-Ribavirin Therapy in Treatment-naive &-experienced Patients with Chronic Hepatitis C Infection
Authors: Mostafa Soliman El-Kady, Mohamed Hatem Wali, Hatem Samir Abd El Raouf, Hany Ragheb Elkholy, Mohamed Morsi Sheta
Year: 2017
Keywords: Sofosbuvir; Standard; Pegylated; Interferon-Ribavirin; ; Chronic Hepatitis C Infection
Journal: Nature and Science
Volume: 15
Issue: 8
Pages: 197-202
Publisher: Not Available
Local/International: International
Paper Link:
Full paper Not Available
Supplementary materials Not Available
Abstract:

Background and study aim: Hepatitis C virus (HCV) is a major cause of liver diseases including chronic hepatitis‚ liver cirrhosis and hepatocellular carcinoma. Egypt has the highest worldwide prevalence of HCV with more than 90% of HCV isolates are genotype 4 variants. To avoid progression of the disease and its complications, antiviral treatment is needed. Genotype-1 infected patients achieved a SVR ranging from 41-52% after 48 weeks of peginterferon-ribavirin with slight higher rates in genotype 4. This study was designed to evaluate the efficacy and safety of adding sofosbuvir to this standard combination therapy in naive patients with chronic hepatitis c and those previously experienced. Patients and methods: Ninety patients with chronic hepatitis c were included in this study. Forty five patients were treatment- naïve while the other 45 patients was failed previous course of pegylated IFN and ribavirin. All patients were evaluated by history, clinical examination, imaging and laboratory investigations. Sofosbuvir was added to the standard combination therapy. Side effects during therapy were observed in patients of both groups to assess safety. Real time quantitative PCR was repeated after 12 weeks from the end of treatment to evaluate sustained virological response (SVR) of patients in both groups to assess efficacy. Results: The overall SVR in all patients was 72.2%. It was achieved in (35/45) patients in the treatment- naïve group (77.8%) while in the experienced one, it was achieved in (30/45) patients (66.7%) with non-significant difference between both groups (p=0.239). In the treatment-experienced group, patients with breakthrough on old regimen (27/45) patients achieved SVR in a significantly lower rate than those in patients with history of relapse (51.9% vs 88.9 % respectively) (p=0.010). The main side effects developed were headache (84.4 & 55.6%), fever (64.4 & 51.1%), bone aches (57.8 & 40%) and asthenia (53.3 & 37.8%) in naïve and experienced groups respectively. headache was significantly more frequent in the treatment-naïve group (p=0.003). Conclusion: Adding sofosbuvir to standard combination therapy (peginterferon-ribavirin) is associated with increased SVR in both treatment-naïve and those experienced with high safety profile in both groups

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus